z-logo
Premium
Identification of CYP 1B1‐specific candidate inhibitors using combination of in silico screening, integrated knowledge‐based filtering, and molecular dynamics simulations
Author(s) -
Kumar Rakesh,
Gupta Dinesh
Publication year - 2016
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12803
Subject(s) - in silico , cyp1b1 , docking (animal) , chemistry , molecular dynamics , quantitative structure–activity relationship , computational biology , virtual screening , drug discovery , active site , stereochemistry , biochemistry , cytochrome p450 , biology , enzyme , computational chemistry , medicine , nursing , gene
CYP 1 B 1 is a promising drug target for developing novel drugs against hormonal cancers and hypertension. The development of CYP 1 B 1‐specific inhibitors is hindered mainly due to non‐specific action of known CYP inhibitors. The active site of CYP 1B1 is similar to other cytochromes with different substrate preferences rendering a scope to develop specific inhibitors. We have developed a novel in silico approach for design of selective CYP 1 B 1 inhibitors. The approach consists of deriving details of CYP 1 B 1‐specific molecular interactions from prior studies, which is used to perform screening of CYP 1 B 1 with NCI compounds. The conventional compound screening is also complemented with the concept of cutoff distance between heme ( F e) and compounds. The binding free energies and HB percentage occupancy calculations of 94 compounds of cluster 1 have verified the docking results using MD . The docking interactions in the active‐site cavity of 7 clusters are also taken into account for optimal binding. Hence, we used knowledgebase filtering and MD simulations to enable discovery of selective CYP 1 B 1 inhibitors. The final filtered lead candidates consist of compounds sandwiched between phenylalanine π–π stacking and less than 6 Å from heme ( F e) for enzymatic action. The findings in the study can help development of novel CYP 1 B 1 selective inhibitors.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom